A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients

OBJECTIVE: To assess the pharmacodynamic effects of sifalimumab, an investigational anti-IFN-α monoclonal antibody, in the blood and muscle of adult dermatomyositis and polymyositis patients by measuring neutralisation of a type I IFN gene signature (IFNGS) following drug exposure. METHODS: A phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Higgs, Brandon W, Zhu, Wei, Morehouse, Chris, White, Wendy I, Brohawn, Philip, Guo, Xiang, Rebelatto, Marlon, Le, Chenxiong, Amato, Anthony, Fiorentino, David, Greenberg, Steven A, Drappa, Jorn, Richman, Laura, Greth, Warren, Jallal, Bahija, Yao, Yihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Basic and Translational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888620/
https://www.ncbi.nlm.nih.gov/pubmed/23434567
http://dx.doi.org/10.1136/annrheumdis-2012-202794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888620/
https://www.ncbi.nlm.nih.gov/pubmed/23434567
http://dx.doi.org/10.1136/annrheumdis-2012-202794

Ejemplares similares